Novavax (NVAX) Asset Writedowns and Impairment (2010 - 2026)

Novavax's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at $266000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $266000.0; the TTM figure through Mar 2026 stood at $99.1 million (up 7732.79% YoY), while the FY2025 annual figure was $4.9 million, up 18.1% from the prior year.
• Asset Writedowns and Impairment was $266000.0 for Q1 2026 at Novavax, down from $1.5 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $155.7 million in Q2 2022 to a low of -$10.1 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $28.4 million across 5 years, with a median of $1.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment slumped 93.53% in 2023, then surged 215.32% in 2025.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $155.7 million in 2022, then plunged by 106.47% to -$10.1 million in 2023, then soared by 87.11% to -$1.3 million in 2024, then soared by 215.32% to $1.5 million in 2025, then sank by 82.24% to $266000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $266000.0 (Q1 2026), $1.5 million (Q4 2025), and $97.0 million (Q3 2025), per Business Quant data.